Balancing benefits and risks in the era of biologics

Giovanni Adami; Kenneth G. Saag; Roland D. Chapurlat; Nuria Guañabens; Glenn Haugeberg; Willem F. Lems; Radmila Matijevic; Nicola Peel; Denis Poddubnyy; Piet Geusens

doi:https://doi.org/10.1177/1759720X19883973

Balancing benefits and risks in the era of biologics

Giovanni Adami, Kenneth G. Saag, Roland D. Chapurlat, Nuria Guañabens, Glenn Haugeberg, Willem F. Lems, Radmila Matijevic, Nicola Peel, Denis Poddubnyy, Piet Geusens

Research output: Contribution to journal › Review article › Academic › peer-review

9 Citations (Scopus)

Abstract

Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.

Original language	English
Article number	11
Journal	Therapeutic Advances in Musculoskeletal Disease
Volume	11
DOIs	https://doi.org/10.1177/1759720X19883973
Publication status	Published - 1 Jan 2019

Keywords

benefit–risk ratio
biologics
denosumab
romosozumab

Access to Document

https://doi.org/10.1177/1759720X19883973

Cite this

@article{7edb4a80cbb149bd8cb547255b654ad5,

title = "Balancing benefits and risks in the era of biologics",

abstract = "Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.",

keywords = "benefit–risk ratio, biologics, denosumab, romosozumab",

author = "Giovanni Adami and Saag, {Kenneth G.} and Chapurlat, {Roland D.} and Nuria Gua{\~n}abens and Glenn Haugeberg and Lems, {Willem F.} and Radmila Matijevic and Nicola Peel and Denis Poddubnyy and Piet Geusens",

year = "2019",

month = jan,

day = "1",

doi = "https://doi.org/10.1177/1759720X19883973",

language = "English",

volume = "11",

journal = "Therapeutic Advances in Musculoskeletal Disease",

issn = "1759-720X",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Balancing benefits and risks in the era of biologics

AU - Adami, Giovanni

AU - Saag, Kenneth G.

AU - Chapurlat, Roland D.

AU - Guañabens, Nuria

AU - Haugeberg, Glenn

AU - Lems, Willem F.

AU - Matijevic, Radmila

AU - Peel, Nicola

AU - Poddubnyy, Denis

AU - Geusens, Piet

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.

AB - Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.

KW - benefit–risk ratio

KW - biologics

KW - denosumab

KW - romosozumab

UR - http://www.scopus.com/inward/record.url?scp=85074160007&partnerID=8YFLogxK

U2 - https://doi.org/10.1177/1759720X19883973

DO - https://doi.org/10.1177/1759720X19883973

M3 - Review article

C2 - 31695755

SN - 1759-720X

VL - 11

JO - Therapeutic Advances in Musculoskeletal Disease

JF - Therapeutic Advances in Musculoskeletal Disease

M1 - 11

ER -

Balancing benefits and risks in the era of biologics

Abstract

Keywords

Access to Document

Other files and links

Cite this